View Post

Study uncovers unknown pathway for breast cancer recurrence

In In The News by Barbara Jacoby

From: business-standard.com The researchers have tracked treatment-resistant cancer cells that grow and spread after the breast cancer treatment. For many women who thought they had beaten breast cancer, the news that it has roared back years later comes as an especially cruel diagnosis with no clear answers for why or how it recurs. Now a team of researchers has filled …

View Post

Breast cancer study by UCR medical student could help patients live longer

In In The News by Barbara Jacoby

By: Iqbal Pittalwala From: ucr.edu A student at the University of California, Riverside, presented research results at the annual meeting of the American Association for Cancer Research, or AACR, in Atlanta showing that surgery is associated with higher survival rates for patients with HER2-positive stage 4 breast cancer compared with those who did not undergo surgery. The protein HER2, or …

View Post

Breast cancer drug approved for Australia

In Clinical Trials by Barbara Jacoby

By: AAP From: 9news.com.au Kate Harper wants to be around to watch her two young twin sons grow up. That’s why, after grappling with the feeling of helplessness that came with being diagnosed with breast cancer, she made a commitment. “I said right from the start – and my husband’s in agreement as well – that we would attack everything …

View Post

Subcutaneous Herceptin Combo Therapy for Certain Breast Cancer Patients Granted FDA Approval

In In The News by Barbara Jacoby

By: Jennifer Barrett From: pharmacytimes.com Officials with the FDA have approved trastuzumab and hyaluronidase-oysk (Herceptin Hylecta, Genentech) subcutaneous injection for certain patients with HER2-positive early and metastatic breast cancer, according to a press release. Trastuzumab and hyaluronidase-oysk is indicated for patients with early disease in combination with chemotherapy, and metastatic disease in combination with paclitaxel, or alone in patients who …

View Post

Collaboration Promises Better, More Accurate Breast Cancer Diagnostics

In In The News by Barbara Jacoby

From: PR Newswire Data-sharing result s in an improved method of HER2 protein analysis which promises more accurate breast cancer diagnosis results. The Health Exchange Market, or T.H.E.M.™, together with LabCorp, Konica Minolta, Inc. University of Rochester, Penn State Hershey Medical Center and Lebanon VA Medical Center, has presented significant findings in breast cancer research at the 2018 San Antonio …

View Post

uBiome Announces First Stage of Companion Diagnostic Development in Collaboration with Puma Biotechnology, Inc.

In In The News by Barbara Jacoby

From: prweb.com uBiome, the leader in microbial genomics, today announced the first stage of companion diagnostic development with Puma Biotechnology, Inc. (NASDAQ: PBYI) to investigate the role of the microbiome in adverse events related to neratinib treatment of patients with HER2-positive breast cancer. “This companion diagnostic and clinical trial work is an important part of the future of uBiome,” said …

View Post

Puma Biotechnology Presents Results of Patient Reported Outcomes in Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

In Clinical Trials by Barbara Jacoby

From: businesswire.com Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, is presenting updated results from a Phase II clinical trial of Puma’s drug neratinib at the 2018 San Antonio Breast Cancer Symposium (SABCS) that is currently taking place in San Antonio, Texas. The presentation entitled, “The impact of neratinib with or without anti-diarrheal prophylaxis on health-related quality of life in …

View Post

New cancer vaccine may tackle HER2-positive tumors

In In The News by Barbara Jacoby

By: Ana Sandoiu From: medicalnewwstoday.com New research shows that a new cancer vaccine may be effective for treating a range of HER2-positive cancers, including the more aggressive HER2-positive breast cancer. Cancer that is human epidermal growth factor 2 (HER2)-positive holds too much of the protein on the surface of its cells. In HER2’s role as a growth factor, normal levels …

View Post

FDA approves new treatment to reduce the risk of breast cancer returning

In In The News by Barbara Jacoby

Source: U.S. Food and Drug Administration From: PR Newswire The U.S. Food and Drug Administration today approved Nerlynx (neratinib) for the extended adjuvant treatment of early-stage, HER2-positive breast cancer. For patients with this type of cancer, Nerlynx is the first extended adjuvant therapy, a form of therapy that is taken after an initial treatment to further lower the risk of …

View Post

EU Recommends Approval of Roche’s Pre-Surgery Breast Cancer Treatment

In In The News, Uncategorized by Barbara Jacoby

From: dddmag.com Roche announced that the EU Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission approves the use of Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy for the neoadjuvant treatment (use before surgery) of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. The EU filing was …